Sapelizumab is a humanized monoclonal antibody antagonist of the interleukin-6 receptor (IL-6R/CD126), engineered with huIgG2 and hukappa chains. It is utilized in research for neuromyelitis optica spectrum disorders (NMOSD), supporting both in vitro mechanistic studies and in vivo preclinical models of autoimmune and inflammatory conditions.
Konzentration:
15.081 mg/mL
Molekulargewicht:
~150 kDa
Reinheit:
97.71% (May vary between batches)
Target-Kategorie:
IL Receptor,Interleukin
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten